HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chemical Safety Improvement Act Promises Stronger EPA Oversight

This article was originally published in The Rose Sheet

Executive Summary

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

You may also be interested in...



Fragrance Industry Focused On IP Protection, Possible TSCA Reform

Attendees and panelists at the International Fragrance Association North America’s annual business meeting identified key issues facing the industry, including intellectual-property protection, potential reforms to U.S. chemicals law and sustainability,

Draft CSIA Bill “Reproduces” TSCA, Endangers State Programs – Critics

Bipartisan bill proposed to update U.S. chemicals regulation – the Chemical Safety Improvement Act – “was written to suit the chemicals industry” and would actually be a step backward from the status quo under TSCA, the Environmental Working Group suggests. Other NGOs and legal experts voiced similar criticisms in letters to key Senate members.

People In Brief

Longtime public-health champion Sen. Frank Lautenberg, D-N.J., passes at the age of 89. More people news.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel